Search

everythinglearnresearchcommunity

for

Search:↓

JAM-A modification speeds up skin wound healing by boosting fibroblast growth.

A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.

Integrin-linked kinase is crucial for melanoblasts to properly colonize the skin.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Recognizing Jacquet's sign helps diagnose and treat traction alopecia accurately.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

JAK inhibitors show promise for treating Alopecia Areata, but more research is needed for better, accessible treatments.

Tissue-engineered skin substitutes can model junctional epidermolysis bullosa and may help develop gene therapy.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Long bean leaf juice significantly promotes hair growth.

Abrocitinib may effectively treat stubborn alopecia universalis.

The STRIPAK complex is crucial for skin cell organization and creating a functional skin barrier.

Baricitinib reduces inflammation and improves cell health in premature aging cells.

Jujube fruit extract may reduce kidney damage from ibuprofen in rats.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

Targeted siRNA therapy may be a promising treatment for KID syndrome by reducing mutant gene expression and improving cell communication.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Mutations in the AP1B1 gene cause a new syndrome with skin, hearing, and developmental issues.

Mutations in NIPAL4 cause skin issues by disrupting lipid layers, but some improvement is seen with topical treatment.

JMJD3 and NF-κB activate Notch1, which is essential for skin cell movement and wound healing.